Oculis has retained commercial rights to all its product candidates in all territories. The company plans to commercialize them directly in key markets and/or distribute through selected pharmaceutical partnerships.
The company is also looking to enrich its pipeline with complementary products for ophthalmic diseases through in-licensing.
